Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology

Molecular Genetics and Metabolism

Volumn 112, Issue 1, 2014, Pages 1-8

  Grabowski, Gregory A ^a   Golembo, Myriam ^b   Shaaltiel, Yoseph ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Protalix Biotherapeutics   (Israel)

Author keywords

Acid glucosidase; Gaucher disease; Inborn errors of metabolism; Lysosomal storage disease

Indexed keywords

BETA GLUCOSIDASE; IMIGLUCERASE; MANNOSE; MANNOSE RECEPTOR; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA; GLUCOSYLCERAMIDASE;

DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME GLYCOSYLATION; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE EXPRESSION SYSTEM; GENETIC MANIPULATION; GOLGI COMPLEX; HUMAN; LYSOSOME STORAGE DISEASE; MACROPHAGE; NONHUMAN; PLANT CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; CARROT; CLINICAL TRIAL (TOPIC); ECONOMICS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PLANT;

DAUCUS CAROTA; MAMMALIA;

CLINICAL TRIALS AS TOPIC; DAUCUS CAROTA; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; PLANT CELLS; PLANTS;

EID: 84899630021     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.02.011     Document Type: Review

References (57)

1. Grabowski G.A., Petsko G.A., Kolodny E.H. Gaucher disease. The Metabolic and Molecular Basis of Inherited Disease 2010, 1-143. McGraw-Hill, New York, NY. C.R. Scriver, A.L. Beudet, W.S. Sly (Eds.).
2. Martins A.M., Valadares E.R., Porta G., Coelho J., Semionato Filho J., Pianovski M.A., Kerstenetzky M.S., Montoril Mde F., Aranda P.C., Pires R.F., Mota R.M., Bortolheiro T.C. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J. Pediatr. 2009, 155(4 Suppl.):S10-S18.
3. Sato Y., Beutler E. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. J. Clin. Invest. 1993, 91:1909-1917.
4. Stahl P.D., Rodman J.S., Miller M.J., Schlesinger P.H. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:1399-1403.
5. Sly W.S., Kaplan A., Achord D.T., Brot F.E., Bell C.E. Receptor-mediated uptake of lysosomal enzymes. Prog. Clin. Biol. Res. 1978, 23:547-551.
6. Furbish F.S., Steer C.J., Krett N.L., Barranger J.A. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta 1981, 673:425-434.
7. Doebber T.W., Wu M.S., Bugianesi R.L., Ponpipom M.M., Furbish F.S., Barranger J.A., Brady R.O., Shen T.Y. Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase. J. Biol. Chem. 1982, 257:2193-2199.
8. Cerezyme [Package Insert] 2009, Genzyme Corporation, Cambridge, MA.
9. VPRIV [Package Insert] 2010, Shire Human Genetic Therapies, Inc., Cambridge, MA.
10. Burrow T.A., Grabowski G.A. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin. Investig. (Lond.) 2011, 1:285-293.
11. Elelyso [Package Insert] 2012, Pfizer Labs, New York, NY.
12. Fox J.L. First plant-made biologic approved. Nat. Biotechnol. 2012, 30:472.
13. Yin J., Li G., Ren X., Herrler G. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J. Biotechnol. 2007, 127:335-347.
14. Hellwig S., Drossard J., Twyman R.M., Fischer R. Plant cell cultures for the production of recombinant proteins. Nat. Biotechnol. 2004, 22:1415-1422.
15. Kaiser J. Is the drought over for pharming?. Science 2008, 320:473-475.
16. Cummings J.F., Guerrero M.L., Moon J.E., Waterman P., Nielsen R.K., Jefferson S., Gross F.L., Hancock K., Katz J.M., Yusibov V. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a phase 1 dose-escalation study in healthy adults. Vaccine 2013 Oct 11, pii: S0264-410X(13)01381-9 http://dx.doi.org/10.1016/j.vaccine.2013.10.017 [Epub ahead of print] PMID: 24126211.
17. Franconi R., Demurtas O.C., Massa S. Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev. Vaccines 2010, 9:877-892.
18. Gomord V., Faye L. Posttranslational modification of therapeutic proteins in plants. Curr. Opin. Plant Biol. 2004, 7:171-181.
19. Durocher Y., Butler M. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 2009, 20:700-707.
20. Liu F., Wu X., Li L., Liu Z., Wang Z. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr. Purif. 2013, 90:104-116.
21. Gomord V., Fitchette A.C., Menu-Bouaouiche L., Saint-Jore-Dupas C., Plasson C., Michaud D., Faye L. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol. J. 2010, 8:564-587.
22. European Medicines Agency Guideline on the quality of biological active substances produced by stable transgene expression in higher plants Available at:, (Accessed: August 29, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003153.pdf.
23. Shaaltiel Y., Bartfeld D., Hashmueli S., Baum G., Brill-Almon E., Galili G., Dym O., Boldin-Adamsky S.A., Silman I., Sussman J.L., Futerman A.H., Aviezer D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 2007, 5:579-590.
24. Van Eck J., Keen P. Continued expression of plant-made vaccines following long-term cryopreservation of antigen-expressing tobacco cell cultures. In Vitro Cell. Dev. Biol. Plant 2009, 45:750-757.
25. Tekoah Y., Tzaban S., Kizhner T., Hainrichson M., Gantman A., Golembo M., Aviezer D., Shaaltiel Y. Glycosylation and functionality of recombinant glucocerebrosidase from various production systems. Biosci. Rep. 2013, 33:771-781. (table).
26. Brumshtein B., Salinas P., Peterson B., Chan V., Silman I., Sussman J.L., Savickas P.J., Robinson G.S., Futerman A.H. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010, 20:24-32.
27. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 1995, 122:33-39.
28. Xu Y.H., Sun Y., Barnes S., Grabowski G.A. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 2010, 5:e10750.
29. Berg-Fussman A., Grace M.E., Ioannou Y., Grabowski G.A. Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J. Biol. Chem. 1993, 268:14861-14866.
30. Bijsterbosch M.K., Donker W., van de Bilt H., van Weely S., van Berkel T.J., Aerts J.M. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur. J. Biochem. 1996, 237:344-349.
31. Phenix C.P., Rempel B.P., Colobong K., Doudet D.J., Adam M.J., Clarke L.A., Withers S.G. Imaging of enzyme replacement therapy using PET. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10842-10847.
32. Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X., Brondyk W., Van P.S., Edmunds T., Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783.
33. Bergmann J.E., Grabowski G.A. Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am. J. Hum. Genet. 1989, 44:741-750.
34. Grace M.E., Newman K.M., Scheinker V., Berg-Fussman A., Grabowski G.A. Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol. Chem. 1994, 269:2283-2291.
35. Lerouge P., Cabanes-Macheteau M., Rayon C., Fischette-Laine A.C., Gomord V., Faye L. N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol. Biol. 1998, 38:31-48.
36. Van Patten S.M., Hughes H., Huff M.R., Piepenhagen P.A., Waire J., Qiu H., Ganesa C., Reczek D., Ward P.V., Kutzko J.P., Edmunds T. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007, 17:467-478.
37. Friedman B., Vaddi K., Preston C., Mahon E., Cataldo J.R., McPherson J.M. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 1999, 93:2807-2816.
38. B. Friedman and M. Hayes, Enhanced in vivo uptake of glucocerebrosidase. Patent Number: 5,549,892, Genzyme Corporation, Cambridge, MA 1996.
39. Elbein A.D., Tropea J.E., Mitchell M., Kaushal G.P. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J. Biol. Chem. 1990, 265:15599-15605.
40. Brumshtein B., Wormald M.R., Silman I., Futerman A.H., Sussman J.L. Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:1458-1465.
41. Berger J., Stirnemann J., Bourgne C., Pereira B., Pigeon P., Heraoui D., Froissart R., Rapatel C., Rose C., Belmatoug N., Berger M.G. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br. J. Haematol. 2012, 157:274-277.
42. Bardor M., Faveeuw C., Fitchette A.C., Gilbert D., Galas L., Trottein F., Faye L., Lerouge P. Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. Glycobiology 2003, 13:427-434.
43. Du H., Cameron T.L., Garger S.J., Pogue G.P., Hamm L.A., White E., Hanley K.M., Grabowski G.A. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J. Lipid Res. 2008, 49:1646-1657.
44. Chargelegue D., Vine N.D., van Dolleweerd C.J., Drake P.M., Ma J.K. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 2000, 9:187-194.
45. ClinicalTrials.gov, National Institutes of Health Plant cell expressed recombinant human glucocerebrosidase extension trial [NCT00705939] Available at:, (Accessed: January 27, 2014). http://clinicaltrials.gov/ct2/show/NCT00705939?term=nct00705939&rank=1.
46. ClinicalTrials.gov, National Institutes of Health Expanded access trial of plant expressed recombinant glucocerebrosidase (prGCD) in patients with Gaucher disease [NCT00962260] Available at:, (Accessed: January 27, 2014). http://clinicaltrials.gov/ct2/show/NCT00962260?term=nct00962260&rank=1.
47. ClinicalTrials.gov, National Institutes of Health Switchover trial from imiglucerase to plant cell expressed recombinant human glucocerebrosidase [NCT00712348] Available at:, (Accessed: January 27, 2014). http://clinicaltrials.gov/ct2/show/NCT00712348?term=nct00712348&rank=1.
48. ClinicalTrials.gov, National Institutes of Health A safety and efficacy study of two dose levels of taliglucerase alfa in pediatric subjects with Gaucher disease [NCT01132690] Available at:, (Accessed: January 27, 2014). http://clinicaltrials.gov/ct2/show/NCT01132690?term=NCT01132690&rank=1.
49. Zimran A., Brill-Almon E., Chertkoff R., Petakov M., Blanco-Favela F., Terreros Munoz E., Solorio-Meza S.E., Amato D., Duran G., Giona F., Heitner R., Rosenbaum H., Giraldo P., Mehta A., Park G., Phillips M., Elstein D., Altarescu G., Szleifer M., Hashmueli S., Aviezer D. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118:5767-5773.
50. Zimran A., Mehta A., Giraldo P., Rosenbaum H., Giona F., Amato D.J., Petakov M., Terreros Munoz E., Solorio-Meza S.E., Duran G., Elstein D., Chertkoff R., Brill-Almon E. Long-term safety and efficacy data of taliglucerase alfa, a plant cell-expressed recombinant glucocerebrosidase, in the treatment of naive Gaucher disease patients: 36-month results [abstract 266]. Mol. Genet. Metab. 2013, 108:S102.
51. Zimran A., Gonzalez-Rodriguez D.E., Abrahamov A., Elstein D., Heitner R., Paz A., Brill-Almon E., Chertkoff R. A multicenter, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease [abstract 2140]. Blood 2012, 120.
52. Pastores G., Shankar S.P., Szer J., Petakov M., Cox T.M., Giraldo P., Rosenbaum H., Amato D.J., Mengel E., Chertkoff R., Almon-Brill E., Zimran A. Plant cell-expressed recombinant glucocerebrosidase: taliglucerase alfa as therapy for Gaucher disease in adults patients previously treated with imiglucerase: 24-month results [abstract 179]. Mol. Genet. Metab. 2013, 108:S73-S74.
53. Kesselheim A.S., Avorn J. The most transformative drugs of the past 25years: a survey of physicians. Nat. Rev. Drug Discov. 2013, 12:425-431.
54. Horizons: a newsletter for the Gaucher community. From the Genzyme Corporation, Genzyme Corporation, C. Alkon, the impact of the first treatment for Gaucher disease Available at:, (Accessed: October 1, 2013). http://www.gaucherdisease.org/horizons/Horizons_FALL_2013.pdf.
55. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes J., Schwartz A.J., Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995, 345:1479-1480.
56. Zimran A., Altarescu G., Philips M., Attias D., Jmoudiak M., Deeb M., Wang N., Bhirangi K., Cohn G.M., Elstein D. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115:4651-4656.
57. Du H., Levine M., Ganesa C., Witte D.P., Cole E.S., Grabowski G.A. The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am. J. Hum. Genet. 2005, 77:1061-1074.